

Comment Info: =================

General Comment:Dear Mr. Zeller:

Today I write to you as an individual consumer to request an extension of the comment period for the Food and Drug Administration's ("FDA") Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. On behalf of myself, I would personally request that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.

The Proposed Rule raises quite a number of significant issues and questions that are important and relevant to me, as a consumer of products I use on a daily basis that are proposed for regulation under the Proposed Rule. The Proposed Rule asks about a hundred different questions I may want to respond to. I want to provide my thoughts and comments on many of these issues, but my time to devote to researching and providing thoughtful, accurate, and relevant comments on these important questions is limited. I have already spent many hours researching and dissecting these issues, but they take time. I know that the FDA took many years to come up with the Proposed Rule, so I do not think it is at all unreasonable to allow the public a six month time frame to comment on it. This I believe is our only opportunity, as consumers, to provide our feedback. And our only opportunity to voice our concerns as consumers under the rules and regulations of the FDA.

I feel very strongly about e-cigarettes, personal vaporizers, and related products to include the liquid for my personal Vaporizer as an alternative to combustible cigarettes. Quite simply, I firmly believe that they saved my life, I know that they have saved me form a diagnoses of COPD/Emphysema . I wish to provide you with my personal story, as well as science- and evidence-based responses to your questions so that you can take my comment into account. I understand that the FDA has the authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here, so that all stakeholders have the opportunity to provide their comments on this proposed regulation.

I appreciate your consideration of my request and am happy to discuss this issue with you further.

Please do not hesitate to contact me to discuss this issue further.


